Pharma CEOs write open letter calling suppliers to commit to sustainability
Several big pharma companies have added their names to a letter challenging suppliers in the healthcare industry to pledge to sustainability targets.
Sustainability targets in the pharmaceutical and other major industries are often scrutinised and their efficacy questioned, as to whether they will lead to meaningful change or whether they are just ‘greenwashing’.
Some global bodies and initiatives have worked to put together targets that are achievable, whilst also making a significant impact on the sustainability across industries.
One such programme in the private sector is the Sustainable Markets Initiative, which sets out a series of targets and provides tools to achieve them, in the healthcare industry.
The initiative is supported by over 500 companies, CEOs, cities, and countries, who came on board since it’s inception in 2020.
Even with this impressive support however, more commitments need to be made to make a tangible difference globally, within the next few years.
To this end, members of the Sustainable Markets Initiative Health Systems Task Force have published an Open Letter to suppliers in the healthcare chain to encourage them to also committing to join the initiative and work towards at least the minimum climate and sustainability targets.
The letter, signed by CEOs of AstraZeneca, GSK, Merck, Novo Nordisk, Sanofi, Samsung Biologics, and the Chairman of Roche, outlines targets tailored specifically for suppliers, to aid them in reducing their emissions, and sets out a level of expectations to be met by suppliers as a universal minimum requirement.
The letter is a hard-hitting and direct declaration of the impact of climate change, stating a rise in global disease burden, with seven million people dying prematurely due to air pollution each year.
The contribution to this from the healthcare industry is about 5%, half of which stems from the supply chain itself. With Net Zero targets looming, the committed companies along with the WHO, are demanding a level of urgency from the rest of the sector to collaborate and accelerate efforts to meet these targets.
The letter states:
“Healthcare supply chains must become greener, more efficient and circular. We must work across the value chain to decarbonise operations, and do all we can to move away from fossil-fuelled heat and power. Having launched a set of core commitments at COP27, we are scaling our impact above and beyond the actions we are taking within our own organisations.”
Some of the joint, minimum targets suggested for suppliers include to assess and disclose Scope 1, 2, and 3 emissions by 2025, to commit to switch to at least 80% renewable power by 2030 (and to make this commitment public), and to adopt water stewardship standards along with targets to increase efficiency of water usage in the supply chain.
These targets were settled upon by seeking the best practices from various contributors in the industry, to include applicable perspectives. Member pharma companies will already start to engage in strategies to meet the targets with their suppliers, with the hope that more will soon follow with this increased support.
Source: Sustainable Markets Initiative. Open Letter to suppliers published by members of the Sustainable Markets Initiative Health Systems Task Force. [Date Accessed 20/07/2023].
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Ardena and RiboPro have formed an alliance to boost their respective skills in manufacturing and producing nanoparticle and mRNA-based therapeutics to improve accessibility to this technology in the biotherapeutic landscape.
Several biosimilars to AbbVie’s monoclonal antibody therapeutic Humira were launched by various pharmaceutical giants this week in the US, with more expected to be released by the end of the year as the patent expires.
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors stateDoctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients.
In our new monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond.
Since the onset of the COVID-19 pandemic, the innovative potential of mRNA vaccines and therapeutics has raised questions regarding their manufacturing, packaging, and storage/transportation. Learn about how the pharmaceutical supply chain is meet...
Download your FREE pharma marketing eBook to learn why it is so important for pharmaceutical marketeers to develop their digital content marketing strategies in order to establish their companies as thought leaders and industry experts.
Novo Nordisk will invest 15.9 billion Danish kroner into the expansion of their existing API manufacturing facility.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
Generate high-quality, engaged leads for your business, all year round
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
Your company’s profile boosted at all participating CPHI events
An easy-to-use platform with a detailed dashboard showing your leads and performance